Titre :

Effect on survival of local ablative treatment of metastases from sarcomas: a study of the french sarcoma group

Auteur(s) :

Falk, A T. [Auteur]
Moureau Zabotto, Laurence [Auteur]
Ouali, M. [Auteur]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Italiano, Antoine [Auteur]
Bay, Jacques-Olivier [Auteur]
Olivier, Thimotee [Auteur]
Sunyach, Marie-Pierre [Auteur]
Boudou-Rouquette, Pascaline [Auteur]
Salas, Sébastien [Auteur]
Le Maignan, Christine [Auteur]
Ducassou, A. [Auteur]
Isambert, Nicolas [Auteur]
Kalbacher, Elsa [Auteur]
Pan, C. [Auteur]
Saada, Esma [Auteur]
Bertucci, François [Auteur]
Thyss, Antoine [Auteur]
Thariat, J. O. [Auteur]

Titre de la revue :

Clinical oncology (Royal College of Radiologists (Great Britain))

Nom court de la revue :

Clin. Oncol.

Numéro :

27

Pagination :

48-55

Date de publication :

2015-01-01

ISSN :

0936-6555

Mot(s)-clé(s) en anglais :

radiotherapy
sarcoma
radiofrequency
oligometastases
metastectomy
Local treatment

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

OBJECTIVE: Recent data suggest that patients with pulmonary metastases from sarcomas might benefit from ablation of their metastases. Some data are available regarding osteosarcomas/angiosarcomas and lung metastases. The ...
Lire la suite >OBJECTIVE: Recent data suggest that patients with pulmonary metastases from sarcomas might benefit from ablation of their metastases. Some data are available regarding osteosarcomas/angiosarcomas and lung metastases. The purpose of this study was to assess the efficacy of local ablative treatment on the survival of patients with oligometastases (one to five lesions, any metastatic site, any grade/histology) from sarcomas. METHODS: A multicentric retrospective study of the French Sarcoma Group was conducted in sarcoma patients with oligometastases who were treated between 2000 and 2012. Survival was analysed using multivariate sensitivity analyses with propensity scores to limit bias. RESULTS: Of the 281 patients evaluated, 164 patients received local treatment for oligometastases between 2000 and 2012. The groups' characteristics were similar in terms of tumour size and remission of the primary tumours. The median follow-up was 25.7 months; 129 (45.9%) patients had died at this point. The median overall survivals were 45.3 (95% confidence interval = 34-73) months for the local treatment group and 12.6 for the other group (95% confidence interval = 9.33-22.9). Survival was better among patients who received local treatment (hazard ratio = 0.47; 95% confidence interval = 0.29-0.78; P < 0.001). Subgroup analyses revealed similar findings in the patients with single oligometastases (hazard ratio = 0.48; 95% confidence interval = 0.28-0.82; P = 0.007); a significant benefit was observed for grade 3, and a trend was observed for grade 2. CONCLUSIONS: Local ablative treatment seemed to improve the overall survival of the patients who presented with oligometastatic sarcomas, including soft tissue and bone sarcomas. The survival benefit remained after repeated local treatments for several oligometastatic events. Surgery yielded the most relevant results, but alternative approaches (i.e. radiofrequency ablation and radiotherapy) seemed to be promising. The relevance of these results is strengthened by our analysis, which avoided biases by restricting the population to patients with oligometastatic disease and used propensity scores.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T16:56:05Z